FR2854074B1 - Utilisation de l'ivermectine pour le traitement de desordres dermatologiques - Google Patents

Utilisation de l'ivermectine pour le traitement de desordres dermatologiques

Info

Publication number
FR2854074B1
FR2854074B1 FR0305048A FR0305048A FR2854074B1 FR 2854074 B1 FR2854074 B1 FR 2854074B1 FR 0305048 A FR0305048 A FR 0305048A FR 0305048 A FR0305048 A FR 0305048A FR 2854074 B1 FR2854074 B1 FR 2854074B1
Authority
FR
France
Prior art keywords
ivermectin
treatment
dermatological disorders
dermatological
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0305048A
Other languages
English (en)
Other versions
FR2854074A1 (fr
Inventor
Vincent Manetta
Gary R Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33104376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2854074(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0305048A priority Critical patent/FR2854074B1/fr
Priority to AU2004231323A priority patent/AU2004231323C1/en
Priority to BRPI0410503A priority patent/BRPI0410503B8/pt
Priority to RU2005136438A priority patent/RU2350333C3/ru
Priority to ES04728811T priority patent/ES2371945T3/es
Priority to CN201310731121.9A priority patent/CN103800353A/zh
Priority to CNA2004800109954A priority patent/CN1777433A/zh
Priority to DK04728811.3T priority patent/DK1620113T3/da
Priority to JP2006505405A priority patent/JP5711867B2/ja
Priority to ARP040101354A priority patent/AR044050A1/es
Priority to SI200431722T priority patent/SI1620113T1/sl
Priority to PT04728811T priority patent/PT1620113E/pt
Priority to KR1020127013727A priority patent/KR101291824B1/ko
Priority to PCT/EP2004/004950 priority patent/WO2004093886A1/fr
Priority to CA2522579A priority patent/CA2522579C/fr
Priority to AT04728811T priority patent/ATE516037T1/de
Priority to KR1020057019402A priority patent/KR101187231B1/ko
Priority to MXPA05011208A priority patent/MXPA05011208A/es
Priority to EP04728811A priority patent/EP1620113B1/fr
Priority to PL04728811T priority patent/PL1620113T3/pl
Priority to PL378932A priority patent/PL378932A1/pl
Publication of FR2854074A1 publication Critical patent/FR2854074A1/fr
Priority to ZA200507346A priority patent/ZA200507346B/xx
Priority to US11/255,910 priority patent/US7550440B2/en
Publication of FR2854074B1 publication Critical patent/FR2854074B1/fr
Application granted granted Critical
Priority to US12/468,287 priority patent/US8080530B2/en
Priority to US12/483,604 priority patent/US8093219B2/en
Priority to CY20111100856T priority patent/CY1111797T1/el
Priority to US13/310,633 priority patent/US8415311B2/en
Priority to JP2012065724A priority patent/JP5538461B2/ja
Priority to US13/529,971 priority patent/US8470788B2/en
Priority to US13/851,816 priority patent/US8598129B2/en
Priority to US14/063,897 priority patent/US8815816B2/en
Priority to US14/337,966 priority patent/US20140336139A1/en
Priority to US14/792,250 priority patent/US20150306027A1/en
Priority to US14/792,201 priority patent/US20150306124A1/en
Priority to HUS1500048C priority patent/HUS1500048I1/hu
Priority to LTPA2015033C priority patent/LTC1620113I2/lt
Priority to LU92915C priority patent/LU92915I2/fr
Priority to CY2016031C priority patent/CY2016031I1/el
Priority to US15/625,362 priority patent/US11033565B2/en
Priority to US15/625,239 priority patent/US20170281663A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0305048A 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques Expired - Fee Related FR2854074B1 (fr)

Priority Applications (40)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
PL378932A PL378932A1 (pl) 2003-04-24 2004-04-22 Zastosowanie ivermectiny do leczenia schorzeń dermatologicznych
PT04728811T PT1620113E (pt) 2003-04-24 2004-04-22 Formulação tópica de ivermectina para o tratamento de condições dermatológicas
RU2005136438A RU2350333C3 (ru) 2003-04-24 2004-04-22 Применение ивермектина для лечения дерматологических расстройств
BRPI0410503A BRPI0410503B8 (pt) 2003-04-24 2004-04-22 composição tópica e uso da composição
CN201310731121.9A CN103800353A (zh) 2003-04-24 2004-04-22 用于治疗皮肤病症的伊维菌素局部制剂
CNA2004800109954A CN1777433A (zh) 2003-04-24 2004-04-22 用于治疗皮肤病症的伊维菌素局部制剂
DK04728811.3T DK1620113T3 (da) 2003-04-24 2004-04-22 Topisk formulering af ivermectin til behandling af dermatologiske lidelser
JP2006505405A JP5711867B2 (ja) 2003-04-24 2004-04-22 皮膚科学的疾患の治療のためのアイバメクチンの使用
ARP040101354A AR044050A1 (es) 2003-04-24 2004-04-22 Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
SI200431722T SI1620113T1 (sl) 2003-04-24 2004-04-22 Topikalna formulacija ivermectina za zdravljenje dermatoloških obolenj
PCT/EP2004/004950 WO2004093886A1 (fr) 2003-04-24 2004-04-22 Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
KR1020127013727A KR101291824B1 (ko) 2003-04-24 2004-04-22 피부과 질병 치료용 이버멕틴의 외용 제형물
ES04728811T ES2371945T3 (es) 2003-04-24 2004-04-22 Formulación tópica de ivermectina para el tratamiento de afecciones dermatológicas.
CA2522579A CA2522579C (fr) 2003-04-24 2004-04-22 Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
AT04728811T ATE516037T1 (de) 2003-04-24 2004-04-22 Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
KR1020057019402A KR101187231B1 (ko) 2003-04-24 2004-04-22 피부과 질병 치료용 이버멕틴의 외용 제형물
MXPA05011208A MXPA05011208A (es) 2003-04-24 2004-04-22 Uso de ivermectina para el tratamiento de desordenes dermatologicos.
EP04728811A EP1620113B1 (fr) 2003-04-24 2004-04-22 Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
PL04728811T PL1620113T3 (pl) 2003-04-24 2004-04-22 Formulacja iwermektyny do stosowania miejscowego do leczenia schorzeń dermatologicznych
AU2004231323A AU2004231323C1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions
ZA200507346A ZA200507346B (en) 2003-04-24 2005-09-13 Topical formulation of ivermectin for the treatment of dermatological conditions
US11/255,910 US7550440B2 (en) 2003-04-24 2005-10-24 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US12/468,287 US8080530B2 (en) 2003-04-24 2009-05-19 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US12/483,604 US8093219B2 (en) 2003-04-24 2009-06-12 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
CY20111100856T CY1111797T1 (el) 2003-04-24 2011-09-07 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
US13/310,633 US8415311B2 (en) 2003-04-24 2011-12-02 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
JP2012065724A JP5538461B2 (ja) 2003-04-24 2012-03-22 皮膚科学的疾患の治療のためのアイバメクチンの使用
US13/529,971 US8470788B2 (en) 2003-04-24 2012-06-21 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US13/851,816 US8598129B2 (en) 2003-04-24 2013-03-27 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US14/063,897 US8815816B2 (en) 2003-04-24 2013-10-25 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US14/337,966 US20140336139A1 (en) 2003-04-24 2014-07-22 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US14/792,201 US20150306124A1 (en) 2003-04-24 2015-07-06 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US14/792,250 US20150306027A1 (en) 2003-04-24 2015-07-06 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
HUS1500048C HUS1500048I1 (hu) 2003-04-24 2015-09-22 Ivermectin helyi kiszerelése dermatológiai állapotok kezelésére
LTPA2015033C LTC1620113I2 (lt) 2003-04-24 2015-09-24 Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
LU92915C LU92915I2 (fr) 2003-04-24 2015-12-17 Ivermectine pour son usage dans le traitement de la rosacée
CY2016031C CY2016031I1 (el) 2003-04-24 2016-09-09 Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
US15/625,362 US11033565B2 (en) 2003-04-24 2017-06-16 Topical application of ivermectin for the treatment of dermatological conditions/afflictions
US15/625,239 US20170281663A1 (en) 2003-04-24 2017-06-16 Topical application of ivermectin for the treatment of dermatological conditions/afflictions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques

Publications (2)

Publication Number Publication Date
FR2854074A1 FR2854074A1 (fr) 2004-10-29
FR2854074B1 true FR2854074B1 (fr) 2007-11-23

Family

ID=33104376

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0305048A Expired - Fee Related FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques

Country Status (11)

Country Link
US (6) US8815816B2 (fr)
KR (1) KR101291824B1 (fr)
CN (2) CN1777433A (fr)
AR (1) AR044050A1 (fr)
AT (1) ATE516037T1 (fr)
DK (1) DK1620113T3 (fr)
ES (1) ES2371945T3 (fr)
FR (1) FR2854074B1 (fr)
PT (1) PT1620113E (fr)
SI (1) SI1620113T1 (fr)
ZA (1) ZA200507346B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
CA2666365C (fr) * 2006-10-12 2016-08-09 Topaz Pharmaceuticals Llc Formulations topiques d'avermectine et procedes d'elimination et de prophylaxie de souches de poux susceptibles et resistantes au traitement
US7953614B1 (en) 2006-11-22 2011-05-31 Dr Systems, Inc. Smart placement rules
ES2719200T3 (es) * 2008-10-29 2019-07-09 Arbor Pharmaceuticals Llc Sistema conservante para formulaciones tópicas terapéuticas basadas en emulsión
CN102784166B (zh) * 2012-08-01 2015-11-25 青岛绿曼生物工程有限公司 治疗家畜螨虫病的复方伊维菌素组合物及其制备方法
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
AU2014356444B2 (en) 2013-11-29 2019-11-21 Galderma Holding SA Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
KR20160137592A (ko) 2014-03-28 2016-11-30 갈데르마 리써어치 앤드 디벨로프먼트 벤조일 퍼옥시드 함유 비-헹굼 화학적 무스
CN104127334A (zh) * 2014-08-19 2014-11-05 杨人源 一种杀菌除螨宠物香波
US10653659B2 (en) 2014-11-20 2020-05-19 Galderma S.A. Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne
FR3041539B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041540B1 (fr) * 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine.
FR3041537B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
FR3041536B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
FR3041535B1 (fr) 2015-09-29 2019-01-25 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.
FR3041538B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041541B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
CA3000898A1 (fr) * 2015-10-13 2017-04-20 Galderma Sa Procede de preparation d'une emulsion stable comprenant une ou de plusieurs avermectines
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
TR201714097A2 (tr) * 2017-09-22 2018-10-22 Assos Ilac Kimya Gida Ueruenleri Ueretim Ve Ticaret Anonim Sirketi İvermekti̇n topi̇k formülasyon
IL307992A (en) 2017-12-15 2023-12-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
WO2019136211A1 (fr) * 2018-01-05 2019-07-11 Attillaps Holdings Traitement de troubles auto-immuns à l'ivermectine
WO2019152560A1 (fr) * 2018-01-31 2019-08-08 Bio33 Degrees, Inc. Compositions et méthodes pour le traitement par voie topique de pathologies dermiques et oculaires
CN108272750A (zh) * 2018-04-25 2018-07-13 菏泽学院 一种治疗动物皮肤疥癣病的软膏剂及其制备方法
WO2021247283A1 (fr) * 2020-06-04 2021-12-09 Amcyte Pharma, Inc. Administration de concentrations micromolaires de composition en aérosol

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA06863A (fr) 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
FR2725369B1 (fr) * 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
US5656280A (en) 1994-12-06 1997-08-12 Helene Curtis, Inc. Water-in-oil-in-water compositions
EP0873127B1 (fr) 1995-09-25 2006-11-15 Ashmont Holdings Limited Compositions anthelmintiques a base de lactone macrocyclique
FR2754452B1 (fr) 1996-10-11 2003-02-14 Oreal Emulsion h/e a forte teneur en electrolytes et leur utilisation en dermo-cosmetique, notamment pour traiter les phenomenes d'irritation et/ou de peaux sensibles
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6521237B2 (en) * 1998-11-12 2003-02-18 Johnson & Johnson Consumer Companies, Inc. Skin care composition
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
CA2473760C (fr) 2002-02-08 2008-11-04 Merck & Co., Inc. Composition topique d'ivermectine
EP1480633A2 (fr) 2002-03-04 2004-12-01 Divergence, Inc. Acide gras nematicide et composes apparentes a des esters d'acide gras
RU2350333C3 (ru) 2003-04-24 2018-08-24 Галдерма С.А. Применение ивермектина для лечения дерматологических расстройств
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme

Also Published As

Publication number Publication date
ZA200507346B (en) 2006-08-30
ATE516037T1 (de) 2011-07-15
US20140336139A1 (en) 2014-11-13
US20140051653A1 (en) 2014-02-20
AR044050A1 (es) 2005-08-24
SI1620113T1 (sl) 2011-10-28
US20150306124A1 (en) 2015-10-29
CN1777433A (zh) 2006-05-24
CN103800353A (zh) 2014-05-21
US8815816B2 (en) 2014-08-26
US20150306027A1 (en) 2015-10-29
US20170281663A1 (en) 2017-10-05
KR101291824B1 (ko) 2013-07-31
DK1620113T3 (da) 2011-09-12
PT1620113E (pt) 2011-09-12
US11033565B2 (en) 2021-06-15
US20170281664A1 (en) 2017-10-05
KR20120062028A (ko) 2012-06-13
FR2854074A1 (fr) 2004-10-29
ES2371945T3 (es) 2012-01-11

Similar Documents

Publication Publication Date Title
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
LU92915I2 (fr) Ivermectine pour son usage dans le traitement de la rosacée
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
PT1446122E (pt) Utilizacao de flibanserina no tratamento de disturbios de desejo sexual
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
DK1304992T3 (da) Topisk gel-fremföringssystem til behandling af hudlidelser
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR2841470B1 (fr) Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2840809B1 (fr) Utilisation d'une fraction hydrophile de fruit de hippophae rhamnoides pour la prevention et le traitement du derme
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
FR2834887B1 (fr) Utilisation d'un extrait d'artemia pour le traitement des peaux agees
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
FR2887456B1 (fr) "composition pour le traitement de la dermite estivale"
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete

Legal Events

Date Code Title Description
TP Transmission of property
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

ST Notification of lapse

Effective date: 20201205